AlphaGrep UK’s TG Therapeutics TGTX Stock Holding History

AlphaGrep UK’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,271	Closed	-$308K	–	953
2026 Q1	$308K	Buy	9,271 +1,833	+25%	+$54.6K	0.09%	491
2025 Q4	$222K	Buy	+7,438	New	+$243K	0.07%	583

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

AlphaGrep UK's TGTX Position: Q2 2026 in Review

AlphaGrep UK sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 9,271 shares — an estimated $308K sold.

AlphaGrep UK first reported a position in TGTX in Q4 2025 and held it in 2 quarters. The position peaked at $308K in Q1 2026. 405 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

AlphaGrep UK reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 9,271 TG Therapeutics shares in Q2 2026, an estimated $308K.
AlphaGrep UK first reported a position in TG Therapeutics in Q4 2025 and held it in 2 quarters.
AlphaGrep UK's TG Therapeutics position peaked at $308K in Q1 2026.
405 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.